Literature DB >> 34189602

Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study.

Vasiliki-Kalliopi Bournia1, Anastasios Kallianos2, Stylianos Panopoulos1, Elias Gialafos1, Lemonia Velentza2, Panayiotis G Vlachoyiannopoulos1, Petros P Sfikakis1, Georgia Trakada3.   

Abstract

Cardiopulmonary Exercise Testing (CPET) is a standardized, non-invasive procedure assessing pulmonary, cardiovascular, hematopoietic, and skeletal muscle functions during a symptom-limited test. Few studies have examined whether CPET is of prognostic value in Systemic Sclerosis (SSc), a disease characterized by highly increased cardiorespiratory morbidity and mortality. To examine the prognostic value of CPET in SSc patients without baseline pulmonary hypertension (PH). Sixty-two consecutive SSc patients underwent CPET, Pulmonary Function Tests (PFTs) and echocardiography at baseline. Four patients with Right Ventricular Systolic Pressure ≥ 40 mmHg, were excluded. Participants repeated PFTs approximately every 3 years. At the end of the follow-up period [median (IQR): 9.79 (2.78) years] patient vital status was recorded. Cox Regression analysis was used to identify predictors of deterioration of PFTs and 10-year survival. Median (IQR) age of 58 patients (90% women) at baseline was 54.0 (15.0) years, whereas 10-year survival was 88%. Baseline respiratory Oxygen uptake (VO2max) predicted PFT deterioration, defined either as a decline in FVC ≥ 10% or a combined decline in FVC 5%-9% plus DLCO ≥ 15%, during follow-up, after correction for age, gender and smoking status (HR: 0.874, 95%CI: 0.779-0.979, p = 0.021). In addition, lower baseline VO2max (HR = 0.861, 95%CI:0.739-1.003, p = 0.054) and DLCO (HR = 0.957, 95%CI: 0.910-1.006 p = 0.088), as well as male gender (HR = 5.68, 95%CI: 1.090-29.610 p = 0.039) and older age (HR = 1.069, 95%CI: 0.990-1.154, p = 0.086) were associated, after adjustment, with an increased risk for death. In the absence of baseline PH, CPET indices may predict pulmonary function deterioration and death in SSc patients during a nearly 10-year follow-up period.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Exercise test; Pulmonary hypertension; Respiratory function tests; Survival; Systemic sclerosis

Mesh:

Year:  2021        PMID: 34189602     DOI: 10.1007/s00296-021-04937-w

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  29 in total

1.  Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension.

Authors:  Gaël Deboeck; Cristina Scoditti; Sandrine Huez; Jean-Luc Vachiéry; Michel Lamotte; Linda Sharples; Christian Melot; Robert Naeije
Journal:  Eur Respir J       Date:  2012-03-22       Impact factor: 16.671

2.  Impaired exercise performance in systemic sclerosis and its clinical correlations.

Authors:  G Cuomo; C Santoriello; F Polverino; L Ruocco; G Valentini; M Polverino
Journal:  Scand J Rheumatol       Date:  2010-08       Impact factor: 3.641

Review 3.  Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement.

Authors:  Luis Puente-Maestu; Paolo Palange; Richard Casaburi; Pierantonio Laveneziana; François Maltais; J Alberto Neder; Denis E O'Donnell; Paolo Onorati; Janos Porszasz; Roberto Rabinovich; Harry B Rossiter; Sally Singh; Thierry Troosters; Susan Ward
Journal:  Eur Respir J       Date:  2016-01-21       Impact factor: 16.671

Review 4.  General considerations for lung function testing.

Authors:  M R Miller; R Crapo; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-07       Impact factor: 16.671

5.  Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort.

Authors:  Stylianos Panopoulos; Vasiliki-Kalliopi Bournia; George Konstantonis; Kalliopi Fragiadaki; Petros P Sfikakis; Maria G Tektonidou
Journal:  Autoimmun Rev       Date:  2018-06-06       Impact factor: 9.754

Review 6.  ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases.

Authors:  Thomas Radtke; Sarah Crook; Georgios Kaltsakas; Zafeiris Louvaris; Danilo Berton; Don S Urquhart; Asterios Kampouras; Roberto A Rabinovich; Samuel Verges; Dimitris Kontopidis; Jeanette Boyd; Thomy Tonia; Daniel Langer; Jana De Brandt; Yvonne M J Goërtz; Chris Burtin; Martijn A Spruit; Dionne C W Braeken; Sauwaluk Dacha; Frits M E Franssen; Pierantonio Laveneziana; Ernst Eber; Thierry Troosters; J Alberto Neder; Milo A Puhan; Richard Casaburi; Ioannis Vogiatzis; Helge Hebestreit
Journal:  Eur Respir Rev       Date:  2019-12-18

7.  Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis.

Authors:  Allan J Walkey; Michael Ieong; Mir Alikhan; Harrison W Farber
Journal:  J Rheumatol       Date:  2010-06-15       Impact factor: 4.666

8.  Exercise testing to estimate survival in pulmonary hypertension.

Authors:  Herman Groepenhoff; Anton Vonk-Noordegraaf; Anco Boonstra; Marieke D Spreeuwenberg; Pieter E Postmus; Harm J Bogaard
Journal:  Med Sci Sports Exerc       Date:  2008-10       Impact factor: 5.411

Review 9.  Musculoskeletal Manifestations of Systemic Sclerosis.

Authors:  Kathleen B Morrisroe; Mandana Nikpour; Susanna M Proudman
Journal:  Rheum Dis Clin North Am       Date:  2015-05-26       Impact factor: 2.670

10.  Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis.

Authors:  Ralf Ewert; Till Ittermann; Dirk Habedank; Matthias Held; Tobias J Lange; Michael Halank; Jörg Winkler; Sven Gläser; Horst Olschewski; Gabor Kovacs
Journal:  BMC Pulm Med       Date:  2019-11-29       Impact factor: 3.317

View more
  1 in total

1.  The Role of Pulmonary Function Test for Pulmonary Arterial Hypertension in Patients with Connective Tissue Disease.

Authors:  Jiangbiao Xiong; Jianbin Li; Yiping Huang; Fan Yang; Rui Wu
Journal:  Dis Markers       Date:  2022-09-29       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.